ATE113203T1 - Darreichnungsform zur verabreichnung eines antiparkinsonsmittel. - Google Patents

Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.

Info

Publication number
ATE113203T1
ATE113203T1 AT91908910T AT91908910T ATE113203T1 AT E113203 T1 ATE113203 T1 AT E113203T1 AT 91908910 T AT91908910 T AT 91908910T AT 91908910 T AT91908910 T AT 91908910T AT E113203 T1 ATE113203 T1 AT E113203T1
Authority
AT
Austria
Prior art keywords
antiparkinsonic
administration
agent
pharmaceutical form
parkinson
Prior art date
Application number
AT91908910T
Other languages
English (en)
Inventor
David Emil Edgren
Howard A Carpenter
Gurdish Kaur Bhatti
Atul Devdatt Ayer
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE113203T1 publication Critical patent/ATE113203T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT91908910T 1990-05-07 1991-05-01 Darreichnungsform zur verabreichnung eines antiparkinsonsmittel. ATE113203T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/520,295 US5190763A (en) 1990-05-07 1990-05-07 Dosage form indicated for the management of abnormal posture, tremor and involuntary movement

Publications (1)

Publication Number Publication Date
ATE113203T1 true ATE113203T1 (de) 1994-11-15

Family

ID=24071988

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908910T ATE113203T1 (de) 1990-05-07 1991-05-01 Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.

Country Status (17)

Country Link
US (1) US5190763A (de)
EP (1) EP0527835B1 (de)
JP (1) JP2634322B2 (de)
KR (1) KR0169146B1 (de)
AT (1) ATE113203T1 (de)
AU (1) AU641770B2 (de)
CA (1) CA2041579C (de)
DE (1) DE69104830T2 (de)
DK (1) DK0527835T3 (de)
ES (1) ES2067231T3 (de)
FI (1) FI925029A0 (de)
IE (1) IE62397B1 (de)
NO (1) NO924209L (de)
NZ (2) NZ238011A (de)
PT (1) PT97552B (de)
WO (1) WO1991016885A1 (de)
ZA (1) ZA913282B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20030056896A1 (en) * 1995-05-12 2003-03-27 Frank Jao Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) * 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
CA2223588C (en) * 1995-06-07 2004-01-06 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid
DE19626621A1 (de) * 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
BR9908713A (pt) 1998-03-16 2000-11-21 Somerset Pharmaceuticals Inc Uso de selegilina ou desmetil-selegilina para tratamento de feridas, queimaduras e danos dermatológicos
DE19855704C2 (de) 1998-12-03 2002-08-01 Lothar Saiger Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
AU783685B2 (en) * 1999-12-23 2005-11-24 Pfizer Products Inc. Hydrogel-driven drug dosage form
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
DK1441708T3 (da) 2001-11-05 2009-07-06 Krele Pharmaceuticals Llc Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
WO2003084514A1 (en) * 2002-04-11 2003-10-16 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of carbidopa and levodopa
EP1622450A4 (de) * 2003-04-25 2009-11-18 Endo Pharmaceuticals Solutions Verfahren zur förderung des durchschlafens durch verabreichung von trospiumchlorid
EP2112920B1 (de) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
JP5160786B2 (ja) * 2003-08-29 2013-03-13 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物及びレボドパ及びカルビドパの使用方法
WO2005072705A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
JP2005309912A (ja) * 2004-04-23 2005-11-04 Oki Data Corp 画像形成装置
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US7342131B2 (en) * 2004-06-04 2008-03-11 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) * 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US8252331B2 (en) * 2004-12-03 2012-08-28 Osmotica Kereskedelmi és Szolgáltató, KFT Osmotic device containing amantadine and an osmotic salt
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
EP2201963B1 (de) 2005-04-05 2016-01-27 Yale University Glutamatmodulationsmittel bei der Behandlung mentaler Störungen
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
EP1959948B1 (de) * 2005-12-05 2012-07-18 XenoPort, Inc. Levodopa-prodrug-mesylat, zusammensetzungen daraus und verwendungen davon
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1970055B1 (de) 2005-12-29 2010-11-24 Osmotica Kereskedelmi És Szolgáltató Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
TW200843732A (en) * 2006-12-21 2008-11-16 Xenoport Inc Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
MX2010013393A (es) † 2008-06-06 2011-06-21 Pharma Two B Ltd Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson.
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
WO2010105093A2 (en) * 2009-03-12 2010-09-16 Delpor, Inc. Implantable device for long-term delivery of drugs
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
CN117860718A (zh) 2017-08-24 2024-04-12 阿达玛斯药物有限责任公司 金刚烷胺组合物、其制备和使用方法
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4235236A (en) * 1979-02-12 1980-11-25 Alza Corporation Device for dispensing drug by combined diffusional and osmotic operations
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4716496A (en) * 1986-05-09 1987-12-29 Eaton Corporation Panel-mounted control station housing

Also Published As

Publication number Publication date
IE62397B1 (en) 1995-01-25
PT97552A (pt) 1992-01-31
WO1991016885A1 (en) 1991-11-14
NZ238011A (en) 1995-12-21
JP2634322B2 (ja) 1997-07-23
NO924209L (no) 1992-11-09
DE69104830D1 (de) 1994-12-01
NO924209D0 (no) 1992-11-02
NZ248491A (en) 1995-12-21
FI925029A7 (fi) 1992-11-06
CA2041579A1 (en) 1991-11-08
CA2041579C (en) 2003-09-30
DE69104830T2 (de) 1995-03-02
IE911466A1 (en) 1991-11-20
KR0169146B1 (ko) 1999-01-15
ZA913282B (en) 1992-02-26
PT97552B (pt) 1998-08-31
EP0527835A1 (de) 1993-02-24
KR930700076A (ko) 1993-03-13
DK0527835T3 (da) 1995-04-18
AU7854391A (en) 1991-11-27
US5190763A (en) 1993-03-02
ES2067231T3 (es) 1995-03-16
JPH05506858A (ja) 1993-10-07
FI925029L (fi) 1992-11-06
EP0527835B1 (de) 1994-10-26
FI925029A0 (fi) 1992-11-06
AU641770B2 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
DE69104830D1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
NO306377B1 (no) Doseform for avgivelse av et medikament
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
ATE129404T1 (de) Dosierungsform fuer die freisetzung eines witkstoffs in einem kurzen zeitraum.
NO920856D0 (no) Innretning for administrering av medikamenter for slimhinnevev
YU215090A (sr) Formulacija u obliku pilule za kontrolisano oslobađanje
NO890186L (no) Fremgangsmaate for fremstilling av en avgivelses- og/ellerdoseringsform for legemiddelaktive stoffer.
YU42397A (sh) Korišćenje raloksifena za pripremu leka
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
NO920854D0 (no) Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
RU94042516A (ru) Способ купирования опийного абстинентного синдрома
KR890015743A (ko) 근섬유아세포의 작용을 개선시키기 위한 tp-수용체 길항제의 용도
SE9101341D0 (sv) New medicinal use
SE8903117D0 (sv) Laekemedel omfattande antamanid
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
KR910005856A (ko) 호흡기 질환 치료용 제약 조성물
RU93043494A (ru) Способ и приспособление для воздействия ультрамалыми дозами лекарственных средств
FR2580502B1 (fr) Emploi du " naftidrofuryl " dans la preparation d'un medicament
RU95101640A (ru) Лекарственное средство для лечения дислипопротеидемии
RU94043033A (ru) Способ коррекции и модуляции иммуногомеостаза при заболеваниях внутренних органов и нервной системы

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee